Streetbeat News

Stock Prices

SYNA

Synaptics (NASDAQ:SYNA) has received diverse analyst ratings in the last three months, with a shift towards more bullish perspectives in the last 30 days. The average 12-month price target for SYNA is $124.83, reflecting a 3.59% increase from the previous target. Despite the positive analyst sentiment, Synaptics faces economic challenges, including a significant revenue decline of -46.95% as of September 30, 2023, and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 8:00 pm

IGMS

IGM Biosciences' stock price is on the rise following an upgrade by RBC Capital from Sector Perform to Outperform, along with an increase in the price target from $9 to $21.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 8:00 pm

CYTK

Over the past 5 years, Cytokinetics (NASDAQ:CYTK) has significantly outperformed the market, with an annualized return of 46.76% and an average annual return of 59.6%, growing a $1000 investment to $10,649.92. The company now has a market capitalization of $7.70 billion.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 8:00 pm

HLI

Houlihan Lokey (NYSE:HLI) has significantly outperformed the market with an average annual return of 22.94% over the past 5 years, turning a $1000 investment into $2,864.43 today. The company's market capitalization stands at $8.67 billion.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 8:00 pm

ATR

AptarGroup's shares experienced an increase following the announcement of their Q4 adjusted EPS results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:55 pm

NGVC

Natural Grocers by Vitamin Cottage (NGVC) shares are trading higher following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:55 pm

CNTA

Centessa Pharmaceuticals' shares surged following the presentation of positive 52-week continuous treatment data from the third year of the ongoing Phase 2a study of SerpinPC for hemophilia treatment.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:50 pm

UI

Ubiquiti shares are trading lower following the announcement of worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:50 pm

BMY

Bristol-Myers Squibb (NYSE:BMY) has seen significant options trading activity, with a bullish sentiment from big-money traders. The trading volume and open interest suggest a focus on a price band between $45.0 and $60.0. Recent trades include both puts and calls, with a notable split in sentiment. Analysts have set an average target price of $52.5, with mixed ratings from Wells Fargo and Redburn Atlantic. The company's stock is currently neutral with a slight increase in price.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 7:45 pm

OWL

Blue Owl Capital's shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:45 pm